J & amp;J Takes Break from Divestitures and Hops on M & amp;A Trail

Apparently two things happen in September: Football season comes back in full swing, and medtech acquisitions begin to pick up. For the third time this week, a new medtech deal has been announced from a larger player in the game. This time out, Johnson & Johnson, through a subsidiary, is acquiring Emerging Implant Technologies Gmbh (EIT), a privately held manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery, for an undisclosed sum. This acquisition allows DePuy Synthes, the orthopedics business of Johnson & Johnson, to enhance its interbody implant portfolio that includes expandable interbody devices, titanium integrated PEEK technology and now 3D-printed cellular titanium, for both minimally invasive and open spinal surgery. The EIT technology complements DePuy Synthes’ investment in the interbody implant segment in spine, including the recent introductions of the CONCORDE LIFT Expandable Interbody Device, and in the U.S., the PROTI 360° Family of Titanium-Integrated Interbody Implants, designed to treat patients with degenerative disc disease. “Our goal is to offer a complete portfolio of interbody solutions that provides surgeons with even more options for the treatment of their patients,” Aldo Denti, Company Group Chairman of DePuy Synthes, said in a statement. M&A hasn’t been a staple of Johnson & Johnson’s strategy ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Orthopedics Source Type: news